Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Editas Medicine (EDIT) Consolidated Net Income (2016 - 2025)

Historic Consolidated Net Income for Editas Medicine (EDIT) over the last 11 years, with Q3 2025 value amounting to -$25.1 million.

  • Editas Medicine's Consolidated Net Income rose 5957.9% to -$25.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$197.6 million, marking a year-over-year increase of 613.13%. This contributed to the annual value of -$237.1 million for FY2024, which is 5637.63% down from last year.
  • As of Q3 2025, Editas Medicine's Consolidated Net Income stood at -$25.1 million, which was up 5957.9% from -$51.5 million recorded in Q2 2025.
  • In the past 5 years, Editas Medicine's Consolidated Net Income ranged from a high of -$18.9 million in Q4 2023 and a low of -$75.7 million during Q1 2025
  • For the 5-year period, Editas Medicine's Consolidated Net Income averaged around -$50.2 million, with its median value being -$51.5 million (2025).
  • Per our database at Business Quant, Editas Medicine's Consolidated Net Income crashed by 52431.9% in 2021 and then skyrocketed by 6894.66% in 2023.
  • Quarter analysis of 5 years shows Editas Medicine's Consolidated Net Income stood at -$41.4 million in 2021, then plummeted by 46.58% to -$60.7 million in 2022, then skyrocketed by 68.95% to -$18.9 million in 2023, then tumbled by 140.68% to -$45.4 million in 2024, then skyrocketed by 44.67% to -$25.1 million in 2025.
  • Its Consolidated Net Income was -$25.1 million in Q3 2025, compared to -$51.5 million in Q2 2025 and -$75.7 million in Q1 2025.